J Eval Clin Pract. 2026 Aug;32(5):e70545. doi: 10.1111/jep.70545.
ABSTRACT
BACKGROUND: The 2026 global consensus proposal published in The Lancet renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS), replacing an anatomically misleading, cyst-centered label with terminology grounded in the disorder's systemic endocrine-metabolic nature. Although PMOS corrects a long-standing mismatch between terminology and evidence, the philosophical, clinical, and social implications of this terminological shift have not been systematically examined.
OBJECTIVE: To critically evaluate the transition from PCOS to PMOS through the lenses of medical nosology, philosophy of language, and Kazem Sadegh-Zadeh's theory of fuzzy medical concepts, assessing both the scientific gains and the new epistemological, clinical, and social challenges introduced by the renaming.
METHODS: This is a conceptual and interpretive analysis rather than an empirical study. Competing models of disease classification (anatomical, symptom-based, eponymous, etiological, and mechanistic) are compared against the PMOS proposal. Sadegh-Zadeh's analytic philosophy of medicine, particularly his account of fuzzy medical concepts, is applied to assess whether PMOS achieves genuine conceptual closure. The analysis draws on the original Lancet consensus statement, empirical reproductive-outcome studies in PCOS, and a comparative precedent from the NAFLD-to-MASLD renaming, to evaluate clinical, psychological, and translatability implications.
RESULTS/DISCUSSION: While PMOS represents a substantial scientific improvement by shifting emphasis from anatomical appearance to the disorder's lifelong metabolic and cardiovascular risks-including elevated odds of myocardial infarction and stroke-it introduces new risks of biomedical reductionism, this time centered on metabolic markers rather than ovarian anatomy. Psychological and social dimensions of the syndrome, including anxiety, depression, and body image distress, remain linguistically invisible in the new name. Retention of the word "ovarian," along with the acronym's phonetic proximity to "PMS," risks re-anchoring the condition to reproductive and gendered framings the renaming sought to escape. Applying Sadegh-Zadeh's framework, PMOS is best understood as an inherently fuzzy construct whose boundaries resist complete biomedical closure, with implications for clinical ownership, multidisciplinary care coordination, cross-cultural translatability, and the practical costs of transitioning established coding, literature, and patient-identity systems.
CONCLUSION: PMOS marks meaningful scientific progress in aligning medical language with the systemic reality of the disorder, yet it is not a definitive terminological solution. Lasting semantic stability requires nomenclature that remains responsive to the multidimensional, lived experience of patients. The shift from PCOS to PMOS should therefore be understood not merely as a linguistic correction but as an ongoing reconstruction of disease ontology itself.
PMID:42550941 | DOI:10.1111/jep.70545